METTL3 and metabolic dysfunction-associated steatotic liver disease: We showed that anti-PD-1 treatment in METTL3 knockout NAFLD-HCC tumors provoked tumor regression by restoring IFN-γ+ and GZMB+ CD8+ T cells.